About this trial
The aims of this study are: To collect biospecimens (including blood, tumour tissue, +/- oral swish, stool, urine, +/-bronchoalveolar lavage/bronchial brushings) for biomarker discovery. To characterise the relationship between host microbiome, genomic and immunologic factors and disease prognosis in patients with malignancies who are receiving or due to receive immune checkpoint inhibitors.
To characterise the relationship between the host microbiome, genomic and immunologic factors and treatment response and/or progression in patients with malignancies who are receiving or due to receive immune checkpoint inhibitors. To characterise the relationship between host microbiome, genomic and immunologic factors and treatment toxicities in patients with malignancies who are receiving or due to receive immune checkpoint inhibitors.
To facilitate further research into potential microbiome/genomic/immunological biomarkers that may be predictive of disease prognosis, treatment response, treatment progression and immune-mediated toxicity in patients with advanced malignancies who are receiving or due to receive immune checkpoint inhibitors.
Patient Profile
Patients with histologically-confirmed malignancy who are candidates for or planned to commence immune checkpoint inhibitor therapy for cancer (either alone or in combination with other anti-cancer treatments).
Where’s this trial being run?
Beaumont Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | GAMBIT |
|---|---|
| Number: | 24-61 |
| Full Title: | Genomic, Acquired Immunologic and Microbial Biomarkers of Immunotherapy Response and Toxicity to Immunotherapy in Cancer. |
| Principal Investigator: | Prof. Jarushka Naidoo |
|---|---|
| Type: | |
| Sponsor: | |
| Recruitment Started: |
Global: Ireland: |
| Global Recruitment Target: | |
|---|---|
| Ireland Recruitment Target: | 240 |